Evidence map›Paper›PMID 42207442›Full record

ArticleMolecular biomedicine2026

CircRNA based bi-antigen vaccines against mpox virus induce potent and durable cross-protection in mice.

Jinge Zhou, Chen Wang, Yan Wu, Baoxin Zhao, Yun Yang, Tianxi Ye, Kaiyue Zhang, Fangxu Li, Jiang Hu, Kai Zhang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jinge Zhou *State Key Laboratory of Virology and Biosafety, Center for Biosafety Mega Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430207, China.
Chen Wang *State Key Laboratory of Virology and Biosafety, Center for Biosafety Mega Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430207, China.
Yan Wu *State Key Laboratory of Virology and Biosafety, Center for Biosafety Mega Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430207, China.
Baoxin ZhaoState Key Laboratory of Virology and Biosafety, Center for Biosafety Mega Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430207, China.
Yun YangResearch and Development Department, Shanghai CirCode Biomedicine Co.Ltd, Shanghai, 200131, China.
Tianxi YeState Key Laboratory of Virology and Biosafety, Center for Biosafety Mega Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430207, China.
Kaiyue ZhangState Key Laboratory of Virology and Biosafety, Center for Biosafety Mega Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430207, China.
Fangxu LiState Key Laboratory of Virology and Biosafety, Center for Biosafety Mega Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430207, China.
Jiang HuResearch and Development Department, Shanghai CirCode Biomedicine Co.Ltd, Shanghai, 200131, China.
Kai ZhangResearch and Development Department, Shanghai CirCode Biomedicine Co.Ltd, Shanghai, 200131, China.
Fang LiuResearch and Development Department, Shanghai CirCode Biomedicine Co.Ltd, Shanghai, 200131, China.
Weiqi WangDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.
Chunhua WangDepartment of Clinical Laboratory, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, 441021, China.
Zefeng WangResearch and Development Department, Shanghai CirCode Biomedicine Co.Ltd, Shanghai, 200131, China. wangzf@sustech.edu.cn.
Xia ChuaiState Key Laboratory of Virology and Biosafety, Center for Biosafety Mega Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430207, China. chuaixia@wh.iov.cn.
Sandra ChiuDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China. qiux@ustc.edu.cn.

Funding

National Key Research and Development Program of China 2022YFC2304102Strategic Priority Research Program of the Chinese Academy of Sciences XDB0490000USTC Research Funds of the Double First-Class Initiative YD9100002040
6 · The paper itself

Abstract

The ongoing epidemic of mpox highlights the urgency of developing novel and effective vaccines against mpox virus (MPXV). Circular RNA (circRNA) has emerged as a promising novel vaccine platform due to its high stability, resistance to exonuclease-mediated degradation, and potential to support prolonged antigen expression. Based on our lipid nanoparticle (LNP)-encapsulated circRNA vaccine platform, we developed two novel bi-antigen circRNA vaccines cirEV and cirMV, which respectively encode the combination of MPXV extracellular enveloped virion (EEV) antigens (A35R and B6R) or intracellular mature virion (IMV) antigens (A29L and M1R). The two MPXV circRNA vaccines alone or mixed as a combination vaccine successfully induce high levels of antigen-specific antibody responses and cellular immune responses against the MPXV antigens and protect mice from lethal vaccinia virus (VACV) challenge in a dose-dependent manner. Furthermore, both circRNA vaccines can provide complete long-term cross-protection against lethal VACV challenge at day 260 after first immunization, indicating the durability of vaccine-induced protective immunity. Notably, vaccine-induced cellular immune responses play a crucial role in immune protection and virus clearance in mice. Our study provides critical insights to understand the protective mechanisms underlying circRNA vaccines in an orthopoxvirus surrogate model, demonstrating that bi-antigen circRNA vaccines represent a promising multivalent vaccine platform.

Indexed as

Antigens, ViralCross ProtectionMpox, MonkeypoxRNA, CircularSmallpox VaccineViral VaccinesAnimalsAntibodies, ViralFemaleImmunity, CellularMiceMice, Inbred BALB CAntibodies, ViralAntigens, ViralRNA, CircularSmallpox VaccineViral VaccinesCircular RNA vaccinesImmune responsesLong-lasting protectionMouse modelMpox virus

Identifiers

PMID42207442
PMCPMC13219560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.